Johnson & Johnson (FRA:JNJ)
165.68
+0.40 (0.24%)
Last updated: Oct 21, 2025, 4:15 PM CET
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B USD in the quarter ending September 30, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.09
Revenue / Employee
$667.26K
Employees
138,100
Market Cap
400.01B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Mercedes-Benz Group AG | 139.36B |
Bayerische Motoren Werke Aktiengesellschaft | 136.51B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Siemens Aktiengesellschaft | 78.30B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Siemens Energy AG | 38.39B |
SAP SE | 35.89B |
Johnson & Johnson News
- 2 days ago - Johnson & Johnson (JNJ) Reports Promising Results for Amivantamab in Cancer Study - GuruFocus
- 2 days ago - Johnson & Johnson (JNJ) Boosts Guidance Amid Strategic Unit Separation - GuruFocus
- 2 days ago - Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer - PRNewsWire
- 4 days ago - Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings? - Nasdaq
- 4 days ago - Dividend Roundup: Citigroup, Johnson & Johnson, Caterpillar, Procter & Gamble, and more - Seeking Alpha
- 4 days ago - Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims - Evening Standard
- 5 days ago - Johnson & Johnson (JNJ) Faces Legal Challenges in UK Over Talc Products - GuruFocus
- 5 days ago - Johnson & Johnson (JNJ) Faces Legal Challenges Over Alleged Asbestos in Baby Powder - GuruFocus